Goingcrazy

Infectious DiseaseClinical Case Presentation: 

Infectious Disease Clinical Case Presentation Samina Syed, MS IV Kees Van Dam, MD September 12, 2007

Slide2: 

CC: Acute mental status changes “I feel like I’m going crazy”

Slide3: 

History of Present Illness R.S. is a 19 year old white male in the Armed Forces, who was preparing for deployment to Iraq during the week of 9/3. The patient’s family visited him over the weekend (9/1-9/2) and he was in a normal state of health aside from complaints of a headache.

Slide4: 

On Monday, 9/3, his father called him around 1300 and was surprised to find him still in bed. His son sounded unusually sleepy. That evening the patient told his mother that he with felt like he was “going crazy.” On 9/4 he did not show up for work.

Slide5: 

On 9/4 he did not show up for work. He was found on his bed nude, mumbling incomprehensible words. He was taken to AF base facility and then to Wayne Memorial. Upon admission, he could state his first name and the year. He began showing signs of frontal disinhibition and rapidly deteriorated.

Slide6: 

He underwent lumbar puncture and was placed on ceftriaxone, vancomycin, and acyclovir. He was intubated for airway protection and transferred to MICU at UNC. Upon arrival patient was minimally responsive to noxious stimuli.

Slide7: 

Past Medical History: Previously healthy SOCIAL HX: Active duty stationed at a nearby airforce base. Deployment week of 9/3/07. Per coworkers, patient does not drink, smoke, or do illicit drugs. Travel: Patient trained in Texas November-April and then moved to North Carolina. He visited family in NY state in July. FAMILY HX: No hx of early CAD HOME MEDICATIONS: mefloquine ALLERGIES: NKDA

Slide8: 

Review of Systems Other than HPI fairly unobtainable. Mother had noticed a rash on his feet bilaterally on Tuesday, 9/5 at Wayne Memorial. She thought it might have been due to the boots he had been wearing.

Slide9: 

Vitals Tmax = 39.4 on admission BP 115/59 RR 20 Physical Exam: General: Intubated, no response to voice. Lymphadenopathy: 1 mm left axillary node Skin: Two to three 1 mm areas with blanching papules bilaterally on the feet. Similar papules were on the dorsum of PIP on left hand and DIP of ring finger on left hand.

Slide10: 

Physical Exam: Neurological Comatose, no response to voice Visual fields show no reaction to threat bilaterally, PERRLA Normal bulk and tone, bilateral upper extremity extensor posturing with nail pressure Slight withdrawal on left lower extremity with nail pressure, slight movement of right quadricep with right lower extremity naill pressure Reflexes symmetric and 3+ bilaterally at bicep, tricep, bracheoradialis, patellar, ankle.

Slide11: 

ADMISSION DIAGNOSTIC STUDIES: (WM)

Slide12: 

ADMISSION DIAGNOSTIC STUDIES

Slide13: 

ADMISSION DIAGNOSTIC STUDIES LP: opening pressure 36 Appearance: colorless clear RBCs 3, WBCs 135 28% neutrophils 59% lymphocytes, 13% monocytes, Glucose 65, Protein 91. CSF Gram stain: No organisms, few WBCs

Slide14: 

ADMISSION DIAGNOSTIC STUDIES CT with and without contrast: showed “no acute intracranial process and no enhancing lesions.” An MRI was performed at Wayne Memorial prior to transfer. MRI also performed at UNC on evening of arrival to MICU.

Slide15: 

MRI BRAIN 9/5/07: T2 Images

Slide29: 

MRI BRAIN: FLAIR Images

Slide43: 

FINDINGS There are large areas of abnormal T2 and FLAIR signal abnormalities involving the subcortical and deep white matter in the bilateral frontal, parietal, and occipital lobes. There is abnormal signal involving the the corpus callosum and periventricular white matter. There is abnormal increased T2 and FLAIR signal involving the medial portions of the temporal lobes and right thalamus. There is similar abnormal signal involving the posterior pons. There is a somewhat linear area of restricted diffusion in the left frontal region just superomedial to the sylvian fissure. This correlates with an area of FLAIR and T2 signal abnormality. There is abnormal FLAIR signal in the subarachnoid spaces bilaterally superiorly. This is nonspecific but can be seen with proteinaceous fluid or subarachnoid hemorrhage but can also be related to ventilation. IMPRESSION 1.Multiple areas of abnormal signal involving predominantly white matter but also areas of gray matter. 2. Nonspecific increased FLAIR signal in the subarachnoid space as described above.

Slide44: 

DISCUSSION

Additional History: Vaccine History: 

Additional History: Vaccine History On 8/18 pt received anthrax vaccine #1, as well as typhoid vaccine IM On 8/23 patient received a smallpox vaccination left deltoid. On 8/30 he received anthrax vaccine #2

Course:: 

Course: Upon arrival to UNC his smallpox vaccination site was examined by Dr. Weber and found to be a “8 mm well scabbed over black eschar on left upper arm.” He had no evidence on exam for satellite lesions. Patient was placed on contact precautions. ICU team added Doxycycline. ID and Neurology were consulted.

Slide47: 

LABS HIV negative RPR NR Crypto ag serum neg B12 normal TSH normal --------------------------------------------------------------------------------------------------- WNV (CSF) VZV PCR (CSF) HSV PCR (CSF) Lyme titer (CSF) Crypto Ag CSF Fungal and AFB stain and culture (CSF) VDRL (CSF)

Course:: 

Course: We recommended addition of high dose ampicillin to cover Listeria in addition to continuing vancomycin, ceftriaxone, acyclovir and doxycycline. Asked MICU to check RMSF titers, arbovirus serologies. We were most concerned for a post vaccinia encephalitis (PVE). Neuro-radiology and Neurology: Imaging, clinical picture c/w Acute Disseminated Encephalomyelitis (ADEM). Neurology recommended high dose steroids and IVIG.

Slide49: 

Consultation with the CDC and DOD on 9/5/07: A second LP at WM had been done on 9/4 with CSF and serum sent to CDC labs. Poxvirology Lab: PCR negative CSF and Blood for poxvirus nucleic acid Serum and CSF IgG negative for poxvirus Serum and CSF IgM pending CDC strongly endorsed adding IVIG to the high dose steroids.

Slide50: 

CDC Conference Call CDC also recommended several additional tests: Pre-IVIG Serum sent to CDC for Poxvirus antibody testing. highly sensitive CRP complement levels and circulating immune complexes EBV, CMV DNA PCR, serologies in blood Chlamydia antibodies Streptoccoccal antibodies Conference calls with the CDC were continued to follow the course of the post vaccinia complication: post vaccinial encephalitis.

Slide51: 

CDC Conference Call: Later that evening the serum and CSF IgM returned positive. Despite lack of evidence for disseminated vaccinia, decided patient might benefit from vaccinia immunoglobulin and CDC shipped VIG overnight to RDU. VIG started on Friday afternoon, IVIG resumed afterwards until pt completed 2g/kg over 4 days. High dose steroids continued.

Course: 

Course Vancomycin, ceftriaxone, doxcycline dc’d after >48 hrs negative cultures, low susp for RMSF. Ampicillin continued until final CSF cultures negative 9/10. Acyclovir continued until CSF HSV, VZV PCR negative 9/11

Course: 

Course West Nile CSF negative Lyme antibody CSF negative RMSF serum IFA 1:80 CDC labs: CSF negative for Adenovirus, Enterovirus, HSV, VZV CDC testing of serum: now positive for IgG on pre IVIG, pre VIG, post VIG serum

Slide54: 

Vaccinia virus is a live DNA virus used as the vaccine against smallpox, which is caused by the Variola virus. Genus: Orthopoxvirus. Day 3-5 Papule Day 5-8 Vesicular Day 8-10 Pustular Day 14-21 Scab separation

Slide55: 

Adverse events after smallpox vaccination recommended for report: Superinfection of the vaccination site or regional lymph nodes Inadvertent inoculation Contact transmission Ocular vaccinia Generalized vaccinia Eczema vaccinatum Progressive vaccinia Erythema multiforme major or SJS Fetal vaccinia Postvaccinial CNS disease Myo/pericarditis Dilated cardiomyopathy

Adverse Events: 

Adverse Events Inadvertent Inoculation Results in a normal vaccinial lesion in an inappropriate site (most common complication in 1968 study).

Adverse Events: 

Adverse Events Generalized Vaccinia Generalized vaccinia is the result of the systemic spread of virus from the vaccination site. Despite the appearance of the lesions, it is usually a benign complication of primary vaccination that is self-limited except in some individuals with underlying immunosuppression (medications or illnesses).

Adverse Events: 

Adverse Events Eczema Vaccinatum A local or disseminated vaccinia that occurs in patients with a hx of eczema or other types of atopic dermatitis Erythema Multiforme Pathogenesis thought to be allergic, toxic, or both.

Adverse Events: 

Adverse Events Progressive Vaccinia (Vaccinia Necrosum) Universally fatal prior to VIG Occurs in immunodeficient vaccinees Progressive destruction of local areas of skin, subcutaneous tissue, and metastatic lesions can lead to death

Adverse Events: 

Adverse Events Myocarditis and Pericarditis Effects range from asx T wave changes to fatal myocarditis. During 2003 civilian first responders vaccination program, 6 out of 10,000 vaccinees developed myocarditis.

Post-Vaccinial Encephalitis: 

Post-Vaccinial Encephalitis Neurological illness is a rare but severe Vaccine Adverse Event (VAER) Post-vaccine Encephalitis (PVE) Historically occurred with greater frequency in first time vaccinees.

Case Definition of PVE for use in Smallpox VAER(Sejvar et al JAMA 2005): 

Case Definition of PVE for use in Smallpox VAER (Sejvar et al JAMA 2005) Confirmed PVE: acute cerebral +/- menningeal inflammation or demyelination on histopathology Probable PVE: Encephalopathy (AMS, personality change) >24 hrs AND Additional features suggestive of cerebral inflammation including 2 or more of following: Fever (>38) or Hypothermia (<35) Meningismus Pleiocytosis Presence of focal neurologic defect EEG c/w encephalitis Neuroimaging (MRI) c/w inflammation or demyelination Seizures AND No alternative etiology Suspected PVE: same as Probable except that only one criteria for cerebral inflammation or demyelination.

Post-Vaccinial Encephalitis: 

Post-Vaccinial Encephalitis Clinicohistopathologic data from the 1920s and 1960s identified 2 clinicopathological forms of PVE: Microglial encephalitis Post-vaccinial encephalopathy

PVE: Microglial encephalitis:: 

PVE: Microglial encephalitis: More frequent in >2 years of age 10-20 days after vaccination Fever, vomiting, headache malaise followed by decreased consciousness, seizures, coma Widespread demyelination of subcortical white matter (prob corresponds to ADEM) ie MRI etc were not available in 1920s, 1960s.

PVE: Post-vaccinial encephalopathy: 

PVE: Post-vaccinial encephalopathy More frequent in <2 years of age 6-12 days after vaccination Fulminant seizures and hemiplegia, elevated ICP. Diffuse cerebral edema and perivascular hemorrhages At times vaccinial viremia and even vaccinia virus isolation/detection from brain or CSF. A neuroinvasive form of vaccinia virus?

Slide66: 

The overall incidence in the U.S. was 2.9/million vaccinees in 1968. The case fatality rate in the U.S. was 25% and 30-50% in Europe (1959-1966). In 2001, the CDC reported the rate as 1 case per 300,000 vaccinees. POST VACCINIAL ENCEPHALITIS

Acute Demyelinating Encephalomyelitis (ADEM): 

Acute Demyelinating Encephalomyelitis (ADEM) ADEM is an immune mediated inflammatory disorder of the CNS, primarily of the white matter, that is typically precipitated by viral infection or vaccination

ADEM: 

ADEM Diagnosis of exclusion Differential: Infection, MS, Transverse Myelitis Based on clinical and radiologic features (MRI critical) Usually monophasic , recurrent ADEM has been reported

Clinical FeaturesADEM: 

Clinical Features ADEM Rapid onset encephalopathy Prodrome with fever, malaise, headache, nausea, vomiting Meningeal signs and drowsiness Rapidly progressive, developing over hours to maximum deficits within days Neurologic signs include acute hemiplegia, ataxia, cranial nerve palsies, seizures, impairment of speech, mental status changes

MRI FeaturesADEM: 

MRI Features ADEM Patchy, poorly marginated areas of increased signal intensity; large, asymmetric, multiple Four patterns: ADEM with less than 5 mm lesions Large, confluent lesions with edema and mass effect ADEM with additional symmetric bithalamic involvement Acute hemorrhagic encephalomyelitis (worst prognosis)

Epidemiology of ADEM: 

Epidemiology of ADEM More common in pediatric patients Recent study of persons less than 20 years with ADEM showed 5% had a vaccination within 1 month, 93% had signs of infection in preceding 21 days Post-vaccinial encephalitis usually occur 7-14 days after vaccination Incidence varies by country

Pathophysiology of ADEM: 

Pathophysiology of ADEM Pathogenesis is not well understood Immune pathogenesis supported by time course between vaccine and encephalitis Similarity in the neuropathology of ADEM with animal models of experimental allergic-autoimmune encephalitis (EAE)

Slide73: 

Pathophysiology of ADEM EAE is an autoimmune disease mediated by T cells directed at myelin antigens Postulated that phosphorylation of myelin basic protein, by vaccinia’s viral kinase, may change the immunogenicity of myelin basic protein Viral epitopes may resemble myelin reactive T cell clones through molecular mimicry

Treatment of ADEM: 

Treatment of ADEM No standard therapy Based on case reports and small series Most therapies use a form of immunosuppressant therapy Steroids IV immunoglobulin Plasmapheresis

Treatment of ADEM: 

Treatment of ADEM IVIG Interaction with Fc receptors on effector cells Anti-idiotypic antibodies against circulating antibodies May alter the number of T cells and subsets Promote clearance of immune deposits May contain neutralizing antibodies May increase clearance of pathogenic IgG May neutralize the inflammatory actions of complement

Treatment of ADEM: 

Treatment of ADEM High dose steroids Gastric perforation, hyperglycemia, hypokalemia, hypertension, facial flushing Plasmapheresis Hypotension, bleeding, allergic rxn, immunosuppresion * Vaccinia immunoglobulin

VIG and ADEM due to PVE?: 

VIG and ADEM due to PVE? Vaccinia Immunoglobulin (VIG) not thought to be useful because PVE thought to be immune mediated, and not due to vaccinial infection. Nanning et al, 1962: Randomized trial of prophylactic VIG in >106,000 Dutch troops vaccinated with smallpox vaccine reduced incidence of PVE from 13 to 3

Prognosis: 

Prognosis Case reports recovery Mild to severe impairment Fatalities ADEM with 15 cases had a 50% recovery rate Pooled summary of case fatality rates (CFR) For every million primary vaccinations 60 cases accidental infection 40 cases of generalized vaccinia 13 cases eczema vaccinatum 3 cases of post-vaccinial encephalitis (CFR 28.9%) 1 case of vaccinia necrosum (CFR 15.4%)

Current clinical course: 

Current clinical course Patient has no spontaneous extremity movements Patient has opened his eyes, and is moving his eyes in response to voice and movement Continue tapering dose of steroids and watch for improvement

References: 

References Aragon et al. Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963-1968. BMC Public Health. Vol.3:26. 2003 Casey et al. Adverse Events Associated with Smallpox Vaccination in the United States, January-October 2003. JAMA. Vol. 294 (21). December 7, 2005. Isascs, S. and Harvey Friedman.Vaccinia Virus as the smallpox vaccine. March 16, 2007. UpToDate [On-Campus Access Only] Kretzschmar et al. Frequency of Adverse Events after Vaccination with Different Vaccinia Strains. PLOS Medicine. Vol 3: 8. August 2006. Lofquist et al. Smallpox: A review of clinical disease and vaccination. American Journal of Health-System Pharmacists. Vol. 60. April 15, 2003.

References (cont’d.): 

References (cont’d.) Menge et al. Acute disseminated encephalomyelitis: an acute hit against the brain. Current Opinion in Neurology. Vol. 20 (3), 247-254. June 2007. Miravalle, A. and Karen Ross. Encephalitis Complicating Smallpox Vaccination. Arch Neurol. Vol. 60; 925-928. July 2003. Sejvar et al. Neurologic Adverse Events Associated with Smallpox Vaccination in the United States, 2002-2004. JAMA. Vol. 294: 21. December 7, 2004. Silvergleid, A. General Principles of the use of IVIG. January 4, 2007 UpToDate (On-Campus Only 7/1/2007) Temembaum et al. Acute Disseminated Encephalomyeltis. Neurology. Vol. 68 (2). April 17, 2007

References (cont’d.): 

References (cont’d.) CDC Surveillance Guidelines for Smallpox vaccine adverse reactions. Vol. 55 (RR01); 1-16. Feb. 3, 2006. CDC Update: Adverse Events Following Civilian Smallpox Vaccination--U.S. 2003. Vol. 52 (20); 475-477. May 23, 2003. CDC Update: Smallpox vaccination and adverse reactions. Vol, 52 (RR04); 1-28. Feb. 21, 2003.

Search PubMed: 

Search PubMed Post-vaccinial encephalitis Case Reports Reviews Differential Diagnosis Drug Therapy